Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 18/20 | 0.85 |
| ▸ | BCL2L1 | Q07817 | 16/20 | 0.85 |
| ▸ | BCL2L2 | Q92843 | 6/20 | 0.72 |
| ▸ | BAD | Q92934 | 2/20 | 0.54 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | ASPH | Q12797 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111891 | 1.00 | BCL2 (0.85) | BCL2BCL2L1BCL2L2BADBCL2L11 | |
| SCHEMBL1678093 | 0.99 | BCL2 (0.84) | BCL2BCL2L1BCL2L2BADBCL2L11 | |
| SCHEMBL1678097 | 0.99 | BCL2 (0.84) | BCL2BCL2L1BCL2L2BADBCL2L11 | |
| SCHEMBL1111909 | 0.95 | BCL2 (0.77) | BCL2BCL2L1BCL2L2BADBCL2L11 | |
| SCHEMBL1111906 | 0.95 | BCL2 (0.77) | BCL2BCL2L1BCL2L2BADBCL2L11 | |
| SCHEMBL1111961 | 0.92 | BCL2 (0.75) | BCL2BCL2L1BCL2L2BAD | |
| SCHEMBL1111965 | 0.92 | BCL2 (0.75) | BCL2BCL2L1BCL2L2BAD | |
| SCHEMBL1679380 | 0.92 | BCL2 (1.00) | BCL2BCL2L1BCL2L2BADBCL2L11 | |
| SCHEMBL1679385 | 0.92 | BCL2 (1.00) | BCL2BCL2L1BCL2L2BADBCL2L11 | |
| SCHEMBL1677647 | 0.92 | BCL2 (0.74) | BCL2BCL2L1BCL2L2BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| EP-2279174-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009143246-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | BCL2 3/4885BCL2L1 13/4885BCL2L2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.